- Home
- PRME vs TERN Comparison
PRME vs TERN Comparison
Compare PRME & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | TERN |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 4.8B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRME | TERN |
|---|---|---|
| Price | $2.70 | $52.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $7.56 | ★ $45.22 |
| AVG Volume (30 Days) | 2.1M | ★ 3.2M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.11 | $2.84 |
| 52 Week High | $6.94 | $53.19 |
Technical Indicators
Market Signals| Indicator | PRME | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 74.51 |
| Support Level | N/A | $52.42 |
| Resistance Level | $3.72 | $53.19 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.07 | -0.31 |
| Stochastic Oscillator | 0.50 | 97.30 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.